Four IPOs are on the schedule for next week. Here is a look at the latest IPO filings and terms added over the last week from the SEC<\/p>\n
<\/p>\n
NEW FILINGS<\/strong><\/p>\n Company: iTeos Therapeutics, Inc. Company: Renalytix AI plc Company: Relay Therapeutics Inc. Company: nCino, Inc. Company: Trean Insurance Group, Inc. Company: Inventive S.A. Company: Nkarta, Inc. TERMS ADDED<\/strong><\/p>\n Company: Dun & Bradstreet Holdings, Inc. Company: Accolade Inc. Company: Lemonade, Inc. Four IPOs are on the schedule for next week. Here is a look at the latest IPO filings and terms added over the last week from the SEC<\/p>\n","protected":false},"author":4,"featured_media":12986,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24,2058,1536],"tags":[],"class_list":["post-13406","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ipo","category-spotlight","category-subscriber-content"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/13406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=13406"}],"version-history":[{"count":4,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/13406\/revisions"}],"predecessor-version":[{"id":13420,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/13406\/revisions\/13420"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media\/12986"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=13406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=13406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=13406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nSymbol: ITOS
\nDescription: They are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients.
\nShares: TBD
\nPrice Range: TBD
\nMarket Cap: TBD
\nTrade Date: TBD
\nUnderwriter(s): JP Morgan, SVB Leerink, Piper Sandler
\nCo-Manager: Wedbush PacGrow
\nFiled: 6-24-20
\nListed Cash Raise: $100m<\/p>\n
\nSymbol:RNLX
\nDescription: They are an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs. Their ordinary shares trade on AIM, a market operated by the London Stock Exchange, under the symbol \u201cRENX.\u201d
\nShares: TBD
\nPrice Range: TBD
\nMarket Cap: TBD
\nTrade Date: TBD
\nUnderwriter(s): JP Morgan, Stifel
\nFiled: 6-24-20
\nListed Cash Raise: $86.25m<\/p>\n
\nSymbol: RLAY
\nDescription:They are a clinical-stage precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology.
\nShares: TBD
\nPrice Range: TBD
\nMarket Cap: TBD
\nTrade Date: TBD
\nUnderwriter(s):JP Morgan, Goldman Sachs, Cowen, Guggenheim Securities
\nFiled: 6-24-20
\nListed Cash Raise: $200m<\/p>\n
\nSymbol: NCNO
\nDescription: nCino is a leading global provider of cloud-based software for financial institutions.
\nShares: TBD
\nPrice Range: TBD
\nMarket Cap: TBD
\nTrade Date: TBD
\nUnderwriter(s): BofA Securities, Barclays, KeyBanc, SunTrust Robinson Humphrey
\nCo-Manager(s): Piper Sandler, Raymond James, Macquarie Capital
\nFiled: 6-22-20
\nListed Cash Raise: $100m<\/p>\n
\nSymbol: TIG
\nDescription: They are an established, growing and highly profitable company providing products and services to the specialty insurance market.
\nShares: TBD
\nPrice Range: TBD
\nMarket Cap: TBD
\nTrade Date: TBD
\nUnderwriter(s): J.P. Morgan,Evercore ISI,William Blair
\nCo-Manager: JMP Securities
\nFiled: 6-19-20
\nListed Cash Raise: $100m<\/p>\n
\nSymbol: IVA
\nDescription: They are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, mucopolysaccharidoses, or MPS, and other diseases with significant unmet medical need. Their ordinary shares are listed on Euronext Paris under the symbol “IVA.”
\nShares: TBD
\nPrice Range: TBD
\nMarket Cap: TBD
\nTrade Date: TBD
\nUnderwriter(s): Jefferies, Stifel, Guggenheim Securities
\nCo-Manager: H.C. Wainwright, Roth Capital Partners, KBC Securities
\nFiled: 6-19-20
\nListed Cash Raise: $90m<\/p>\n
\nSymbol: NKTX
\nDescription: They are a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer, or NK, cell therapies to treat cancer.
\nShares: TBD
\nPrice Range: TBD
\nMarket Cap: TBD
\nTrade Date: TBD
\nUnderwriter(s): Cowen, Evercore, Stifel, Mizuho
\nFiled: 6-19-20
\nListed Cash Raise: $100m<\/p>\n
\nSymbol: DNB
\nDescription: Dun & Bradstreet is a leading global provider of business decisioning data and analytics.
\nShares: 65.75 million
\nPrice Range: $19.00-$21.00
\nMarket Cap: $7.6b-$8.4b
\nTrade Date: Wednesday, 7\/1
\nUnderwriter(s): Goldman Sachs, BofA Securities, J.P. Morgan, Barclays, Citigroup, Credit Suisse, HSBC, Jefferies, RBC Capital Markets, Wells Fargo, Deutsche Bank Securities, BMO Capital Markets, SunTrust Robinson Humphrey, TD Securities
\nCo-Manager(s): Raymond James, Stephens, William Blair, Academy Securities, Loop Capital Markets
\nTerms Added: 6-24-20<\/p>\n
\nSymbol: ACCD
\nDescription: They provide personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits.
\nShares: 8.75 million
\nPrice Range: $19.00-$21.00
\nMarket Cap: $886m-980m
\nTrade Date: Thursday, 7\/1
\nUnderwriter(s): Goldman Sachs, Morgan Stanley, BofA Securities, Piper Sandler, Credit Suisse, William Blair
\nCo-Manager(s): Baird, SVB Leerink
\nTerms Added: 6-24-20<\/p>\n
\nSymbol: LMND
\nDescription: Lemonade is rebuilding insurance from the ground up on a digital substrate and an innovative business model.
\nShares: 11 million
\nPrice Range: $23.00-$26.00
\nMarket Cap: $1.3b-$1.43b
\nTrade Date: Thursday, 7\/2
\nUnderwriter(s): Goldman Sachs, Morgan Stanley, Allen & Co., Barclays
\nCo-Manger(s): JMP Securities, Oppenheimer, William Blair, LionTree
\nTerms Added: 6-25-20<\/p>\n","protected":false},"excerpt":{"rendered":"